CDK4 and cancer: Comparisons with standard‐of‐care chemotherapy have given weight to the notion that CDK4/6 inhibitors may be able to replace conventional chemotherapy in this cancer subtype, which represents the majority of metastatic breast cancers (Giuliano et al, 2019; Nasrazadani & Brufsky, 2019; Tolaney et al, 2020).